Clinical trials: HBV
Hepatitis B
A Study of the Immune Response to Heplisav in Healthy Older Adults
This study will investigate the response of the immune system to a hepatitis B (HB) vaccine in healthy adults 50 to 70 years of age. This study is partially funded by the National Institute of Allergy and Infectious Diseases.
- Trial name
- NCT01999699
- Testing
- HEPLISAV
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Dynavax Technologies Corporation
Chronic Hepatitis B
Safety and Efficacy Study of NVR 3-778 in Healthy Volunteers and Hepatitis B Patients
This Phase 1 trial will assess the dose-related safety and PK profile of different doses of NVR 3-778, first in healthy volunteer subjects (part I) and subsequently in patients with chronic hepatitis B (part II).
- Trial name
- NCT02112799
- Testing
- NVR 3-778, Pegasys
- Where
- 2 sites in New Zealand
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Novira Therapeutics, Inc.
Hepatitis b Vaccine
Assessment of HBV Vaccine Immunity After 18 Years
The purpose of this study is to assess HBV immunity and institute policy regarding the Hepatitis B vaccination practices in the IDF among a cohort that was vaccinated during infancy.
- Trial name
- NCT01590381
- Where
- Israel
- Volunteers
- 545 people, healthy volunteers welcome
- Sponsor
- Medical Corps, Israel Defense Force
Diphtheria, Tetanus
Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™
This is a follow-up of Study A3L11 (NCT00404651). Immunogenicity To describe the antibody persistence following a primary series vaccination of either DTaP-IPV-Hep B-PRP~T or Infanrix hexa™.
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT00654901
- Testing
- DTaP-IPV-Hep B-PRP~T vaccine (Batch 1), DTaP-IPV-Hep B-PRP~T vaccine (Batch 2), DTaP-IPV-Hep B-PRP~T vaccine (Batch 3)
- Where
- 4 sites in Mexico
- Volunteers
- 881 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Vaccine Reaction
Understanding Poor Vaccine Responses to Hepatitis B Vaccination
Vaccines have prevented countless infections but poor vaccine responses remain a major challenge in many scenarios. Hepatitis B vaccine nonresponses are common but immunologically not well-understood.
- Trial name
- NCT04674462
- Testing
- CpG-adjuvanted HBV Vaccine, Traditional HBV Vaccine
- Where
- United States
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Hepatitis B
Evaluation of Immunogenicity and Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine
The purpose of the present trial is to evaluate 6 vaccine formulations of recombinant hepatitis B vaccine for their reactogenicity and immunogenicity when administered at 0-2 months with a booster at month 12
- Trial name
- NCT00697970
- Testing
- HBsAg formulated with different concentrations of MPL and Aluminium Salts, Engerix™-B
- Where
- Austria
- Volunteers
- 321 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B
Thousand Asian American Study
The "Thousand Asian American Study" or "TAAS" aims to test 2,000 foreign-born and children of foreign born Asian Americans residing in Sacramento county residents for HBV and (2) counsel at least 90% of those whose screening…
- Trial name
- TAAS (NCT02596438)
- Testing
- Hepatitis B
- Where
- United States
- Volunteers
- 1,076 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Hepatitis B, Chronic
A Study to Evaluate the Safety and Efficacy of AHB-137 in Healthy Participants and HBeAg-negative Chronic Hepatitis B (CHB) Patients
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of AHB-137 subcutaneous injection in healthy participants after single and multiple doses, and evaluate the preliminary efficacy of AHB-137…
- Trial name
- NCT06115993
- Testing
- AHB-137 injection
- Where
- 3 sites in China
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Ausper Biopharma Co., Ltd.
HIV Infection, Chronic Hepatitis B
Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France
Populations from Sub-Saharan Africa represent one of the most dynamic immigration flows in France and are among the most exposed to HIV infection and hepatitis B.
- Trial name
- PARCOURS (NCT02566148)
- Volunteers
- 2,468 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatic Insufficiency
Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment
The primary objectives were: To determine the effects of steady state TPV co-administered with low dose RTV on steady state PegIFN and RBV in HIV negative subjects with mild hepatic impairment (scheme A) To determine the effects…
- Trial name
- NCT02259855
- Testing
- Tipranavir, Ritonavir, Pegylated interferon
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Renal Insufficiency, Tenofovir
TDF Dose Adjustment VS. Switching to TAF in TDF-experienced CHB Patients With Renal Impairment
Tenofovir is a nucleotide analog drug that works against both Human immunodeficiency virus (HIV) and HBV. TDF and TAF are prodrug of Tenofovir.
- Trial name
- NCT04391608
- Testing
- Switching to Tenofovir Alafenamide
- Where
- Thailand
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Contraception
Acceptability of Depo-subQ in Uniject
This is an observational study to assess the experience of current depot medroxyprogesterone acetate (DMPA) intramuscular (IM) clients and providers when they try Depo-subQ in Uniject and offer recommendations for the…
- Trial name
- NCT01667276
- Where
- 2 sites in Senegal, Uganda
- Volunteers
- 476 people, healthy volunteers welcome
- Sponsor
- FHI 360
Hepatitis B
Evaluate Immune Response Approximately 5 to 6 Years After Receiving Different Formulations of GSK Bio Hep B Vaccine
To evaluate the persistence of antibodies against hepatitis B, approximately 5 to 6 years after the first dose of the hepatitis B in the primary vaccination study.
- Trial name
- NCT00329576
- Testing
- Hepatitis B vaccine
- Where
- 3 sites in Belgium, Germany and 1 more
- Volunteers
- 632 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B
Immunogenicity & Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine With Different Adjuvants
The purpose of this study is to evaluate the immunogenicity and reactogenicity of various formulations of recombinant hepatitis B vaccine with different adjuvants in healthy adult volunteers following the 0, 1, 6 months schedule
- Trial name
- NCT00697125
- Testing
- Engerix™-B, HBV-MPL vaccine (208129), Hepatitis B vaccine, experimental formulation
- Where
- Belgium
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tetanus, Poliomyelitis
Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)
This study is designed to evaluate the safety and immunogenicity of new formulations of GSK Biologicals' DTPa-HBV-IPV/Hib vaccine (GSK217744) when administered as a primary vaccination course to healthy infants at 2, 3 and 4…
- Conditions
- Tetanus, Poliomyelitis, Hepatitis B, Haemophilus Influenzae Type b
- Trial name
- NCT01248884
- Testing
- Infanrix hexa™, Prevenar 13®, GSK217744
- Where
- 16 sites in Dominican Republic, Finland
- Volunteers
- 721 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diphtheria, Acellular Pertussis
Immunogenicity & Safety of GSK's Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination Schedules
In this study, infants who were previously vaccinated with hepatitis B vaccine at birth will be randomly allocated into two groups: one group of subjects will receive diphtheria, tetanus, acellular pertussis- hepatitis B…
- Conditions
- Diphtheria, Acellular Pertussis, Tetanus, Haemophilus Influenzae Type b
- Trial name
- NCT00316147
- Testing
- DTPa-HBV-IPV/Hib vaccine
- Where
- 4 sites in India
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B
Safety, Tolerability and Pharmacokinetics of NCO-48 Fumarate in Healthy Subjects
The primary objective is to evaluate the safety and tolerability of single oral doses of NCO-48 Fumarate in healthy subjects. The secondary objectives are to evaluate the pharmacokinetic (PK) profile of NCO-48 Fumarate and its…
- Trial name
- NCT04309526
- Testing
- NCO-48 Fumarate
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Nucorion Pharmaceuticals, Inc.
Hepatitis B
Expression of Th9 Cells and Poor/Non-responsiveness to Hepatitis B Vaccination
An observational study will be performed in subjects aged 3-65 years old to describe the dynamic changes of cellular immunity after vaccination of hepatitis B vaccine, and to find out the expression levels of Th9 cells and IL9 in…
- Trial name
- NCT01441609
- Where
- China
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Beijing Municipal Science & Technology Commission
Hepatitis B
A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination (V419-013)
The purpose of this study is to demonstrate the durability of protection against hepatitis B virus (HBV) infection approximately 8-9 years after vaccination with Vaxelis®.
- Trial name
- NCT04490499
- Testing
- HBVAXPRO™
- Where
- 10 sites in Finland
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis B
Bioequivalence of LB80380 Free Base and Maleate Salt Tablets
The study is to compare pharmacokinetics of LB80331 and LB80317, which are the metabolites of LB80380, after a single oral administration of LB80380 free base 150 mg (60 mg + 90 mg) tablet or LB80380 maleate tablet 183 mg (150 mg…
- Trial name
- NCT01427868
- Testing
- LB80380 maleate salt, LB80380 free base
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences